Search
Influenza A virus A/South Australia/34/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15621ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Influvac Tetra, suspension for injection in pre-filled syringeNicotine
go.drugbank.com/drugs/DB00184ApprovedInvestigationalNicotine is also important medically because of its presence in tobacco smoke.
Categories: Drugs Used in Addictive Disorders, Drugs Used in Nicotine DependenceSynonyms: 3-(N-methylpyrollidino)pyridine, 3-(2-(N-methylpyrrolidinyl))pyridineDostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigationalA prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.[A248905] … [L33340] This indication was granted full FDA approval on February 10, 2023.[L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month.
Mipomersen
go.drugbank.com/drugs/DB05528ApprovedSpecifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported. … Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.
Categories: Compounds used in a research, industrial, or household settingGadodiamide
go.drugbank.com/drugs/DB00225ApprovedInvestigationalGadodiamide is a linear, non-ionic gadolinium-based contrast agent (GBCA) that is used in magnetic resonance imaging (MRI) procedures to assist in the visualization of blood vessels. … [A263096] Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used.
Categories: Compounds used in a research, industrial, or household settingProducts: OMNISCAN INJECTION 0.5MMOL/ML-10ML IN GLASS VIAL, OMNISCAN INJECTION 0.5MMOL/ML-20ML IN GLASS VIALGlyburide
go.drugbank.com/drugs/DB01016ApprovedInvestigational[A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120] … [L8123] Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations.
Categories: Drugs Used in DiabetesSynonyms: 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamideChlorobutanol
go.drugbank.com/drugs/DB11386ApprovedVet approvedWithdrawnChlorobutanol, or chlorbutol, is an alcohol-based preservative with no surfactant activity [A32746]. … Similar in nature to chloral hydrate, it is formed by the simple nucleophilic addition of chloroform and acetone.
Categories: Compounds used in a research, industrial, or household settingInsulin aspart
go.drugbank.com/drugs/DB01306ApprovedInvestigationalInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able … As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin aspart, to lower glucose levels in the blood.
Categories: Drugs Used in DiabetesProducts: NovoRapid FlexPen 100U/ml solution for injection in pre-filled pen, RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/mlCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.